Slide 1: Analyst presentation 2026 half-year results
Winning together as a team Analyst presentation 2026 half-year results 29 July 2026
Slide 2: Presenting team
Presenting team Marcus Jordan Hans Kooijmans CEO CFO 2
Slide 3: Agenda
1 Highlights HY 2026 2 Financials HY 2026 3 Outlook 4 Q&A 5 Annex 3
Slide 4: Highlights HY 2026: Financial results
Highlights HY 2026: Financial results Cash earnings Gross profit Operating EBITA Net Result Free cash flow per share EUR 658 million EUR 285 million EUR 142 million EUR 222 million EUR 3.18 +7% on a constant +8% on a constant +14% on a constant HY 2025: EUR 173 HY 2025: EUR 2.94 currency basis curre
Slide 5: Highlights HY 2026: M&A
Highlights HY 2026: M&A ● Dong Yang (South Korea) – Beauty and personal care (signed October 2025, closed January 2026) ● Willows (Ireland/UK) – Food and nutrition (signed February 2026, closed March 2026) ● Merit Solutions (Thailand) – Advanced materials (signed June 2026) Three acquisitions adding
Slide 6: Progress on the six strategic pillars that drive our growth
Progress on the six strategic pillars that drive our growth • Strengthening our senior leadership • 3 acquisitions across segments and • Strengthening lab network and and commercial teams regions capabilities • Continued focus on internal talent • Further strengthening of supplier • Increased sales
Slide 7: Financials HY 2026
Highlights Financials Outlook Q&A Annex HY 2026 HY 2026
Slide 8: Financials HY 2026 – income statement
Financials HY 2026 – income statement Jan. 1 - Jan. 1 - Jun. 30, Jun. 30, FX adj. EUR million 2026 2025 Change Change % change Revenue 2,638 2,474 164 7% 11% Gross profit 658 634 24 4% 7% Gross profit as a % of revenue 24.9% 25.6% (0.7%) Operating EBITA 285 275 10 4% 8% Operating EBITA as a % or rev
Slide 9: Financials HY 2026 – segment information
Financials HY 2026 – segment information Asia- Holding EUR million EMEA Americas Pacific companies Total Gross profit YTD Q2 2026 328 176 154 658 YTD Q2 2025 293 191 150 634 organic growth 5% (5%) 3% 2% acquisition growth 8% 1% 7% 5% currency impact (1%) (4%) (7%) (3%) Operating EBITA YTD Q2 2026 14
Slide 10: Financials HY 2026 – income statement
Financials HY 2026 – income statement Jan. 1 - Jun. 30, Jan. 1 - Jun. 30, FX adj. EUR million 2026 2025 Change Change % change Operating EBITA 285 275 10 4% 8% Net finance costs (35) (44) 9 Amortisation of intangible assets (52) (50) (3) Acquisition costs and results related to one-off adjustments t
Slide 11: Financials HY 2026 – net finance costs
Financials HY 2026 – net finance costs Jan. 1 - Jun. 30, Jan. 1 - Jun. 30, EUR million 2026 2025 Change Net interest costs financing structure (32) (28) (4) Interest costs lease liabilities (2) (2) - Changes in deferred considerations 1 7 (6) Interest costs re employee benefits (0) (0) 0 Hyperinflat
Slide 12: Financials HY 2026 – balance sheet
Financials HY 2026 – balance sheet EUR million 30/06/2026 31/12/2025 Change Property, plant and equipment 60 60 - Right-of-use assets 92 98 (6) Intangible assets 2,664 2,658 6 Other financial assets/ deferred tax assets 21 25 (4) Total working capital 1,029 934 95 Provisions/ employee benefits (41)
Slide 13: Financials HY 2026 – year-end working capital
Financials HY 2026 – year-end working capital EUR m 30/06/2026 31/12/2025 30/06/2025 776 756 703 993 769 846 89 84 70 (442) (563) (648) (181) (146) (182) EUR million 30/06/2026 31/12/2025 30/06/2025 Inventories in days of revenue1 53 51 54 Trade receivables in days of revenue1 68 56 60 Trade payable
Slide 14: Financials HY 2026 – net debt
Financials HY 2026 – net debt EUR million 30/06/2026 31/12/2025 Change Loans and borrowings long term 1,074 1,378 (304) Maturity profile as of 30 June 2026 Loans and borrowings short term 375 325 50 EUR million Short term financial liabilities 359 87 272 1,400 Cash and cash equivalents (249) (239) (
Slide 15: Financials HY 2026 – Free cash flow
Financials HY 2026 – Free cash flow Jan. 1 - Jun. 30, Jan. 1 - Jun. 30, EUR million 2026 2025 Change Change % Operating EBITA 285 275 10 4% Depreciation 22 20 2 8% Operating EBITDA 306 295 11 4% Lease payments (17) (16) (1) 7% Share based payments 2 2 (0) (2%) Adjusted EBITDA 291 281 10 4% Capex (3)
Slide 16: Outlook
Highlights Financials Outlook Q&A Annex HY 2026 HY 2026
Slide 17: Outlook
Outlook IMCD operates in different, often fragmented market segments in multiple geographic regions, connecting many customers and suppliers across a very diverse product range. In general, results are impacted by macroeconomic conditions and developments in specific industries. Results may be affec
Slide 18: Q&A
Highlights Financials Outlook Q&A Annex HY 2026 HY 2026
Slide 19: Annex
Highlights Financials Outlook Q&A Annex HY 2026 HY 2026
Slide 20: We are IMCD
We are IMCD IMCD is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. ● Adaptable business model driving simplification for our partners ● Formulatory and solutions provider ● Comprehensive and complementary specialty portfolio ● Global footprint
Slide 21: 8 business groups, focusing on strategic market segments
8 business groups, focusing on strategic market segments Pharmaceuticals Coatings & Construction Food & Nutrition Advanced Materials Excipients; APIs; nutraceuticals; Coatings; decorative paints; Dairy; savoury; bakery; beverage; Compounders; converters; synthesis; agrochemicals; adhesives & sealant
Slide 22: High scores on external ESG ratings
High scores on external ESG ratings Demonstrating our continuous focus on best practices B- (Prime) ESG Risk Score C (2025) Rating A (2026) rating Platinum (2025) Rating 11.6, Score B (2024) on a scale of C+ rating (2024) Gold (2024) low risk (2025) On a scale of A AAA-CCC On a scale of A+ 12.6 (202
Slide 23: Disclaimer
Disclaimer This presentation may contain forward looking statements. These statements are based on current expectations, estimates and projections of IMCD’s management and information currently available to the company. IMCD cautions that such statements contain elements of risk and uncertainties th